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To the Editor,
Mendelian susceptibility to mycobacterial diseases (MSMD;
Online Mendelian Inheritance in Man, OMIM #209950) is an
inborn error of immunity (IEI) characterized by extreme suscep-
tibility to invasive infections sustained by poorly virulent
mycobacteria, including Mycobacterium bovis, bacillus
Calmette-Guérin (BCG) vaccines, and environmental
mycobacteria [1–4].M. tuberculosismay also be involved in rare
cases [5]. Many genes involved in interferon (IFN)-γ production
(IL12B, IL12RB1, IL12RB2, IL23R, TYK2, ISG15, RORC), in
response to IFN-γ (IFN-γR1, IFN-γR2, STAT1, JAK1, CYBB),
both (IRF8, SPPL2A, NEMO) or IFN-γ itself are responsible for
MSDM [4–8]. The clinical features depend on the genotype and
the residual activity of IFN-γ.
IFN-γR is a tetramer composed of two IFN-γR1 and two
IFN-γR2 subunits. IEI in both subunits have been described
and are responsible forMSMD. Autosomal recessive (AR) com-
plete IFN-γR1 or IFN-γR2 deficiencies constitute the most se-
vere forms of MSMD and often have fatal outcome. In these
patients, the clinical manifestations begin in the first years of life
and are characterized by severe, disseminated, and recurrent my-
cobacterial infectious diseases that require prolonged multiple
antibiotic therapy [2, 3]. Exogenous IFN-γ administration is
mostly ineffective when no IFN-γ response could be achieved
and therefore hemopoietic stem cell transplantation (HSCT) is
the only curative intervention, although a high rate of rejection
has been reported in these patients [9–14]. IFNγ-R2 deficiency is
rare; the gene maps to 21q22.1-22-2. From the first report [15],
eleven patients from eight kindreds with AR complete IFN-γR2
deficiency have been described [16–20]. Here, we report a pa-
tient with AR complete IFN-γR2 deficiency (OMIM #147569)
who had severe recurrent infections withMycobacterium avium
and was successfully treated with HSCT from a matched unre-
lated donor.
The child was a singleton born from unrelated Rumanian
parents, after uneventful, at term pregnancy. He grew regularly
and his personal history was unremarkable until 2 years of age
when he had fever and cough for 1 week. Given the clinical and
radiological diagnosis of left pneumonia, he was hospitalized. At
physical examination, there were pallor, diffuse lymphadenopa-
thy, andmoderate hepatosplenomegaly.White blood cell (WBC)
count (36,980/uL, N 68%) and inflammatory indices (C-reactive
protein 156 mg/L, erythrocyte sedimentation rate 106 mm) were
markedly increased. He started antibiotic therapy with intrave-
nous ceftriaxone and then switched to meropenem and subse-
quent administration of teicoplanin plus azithromycin with no
clinical improvement and persistently increased inflammatory
markers. No microorganism was isolated in repeated cultures
from blood, oropharyngeal swabs, and urines. Pulmonary com-
puted tomography [CT] scan documented a parenchymal con-
solidation in the left upper lobe with diffuse lymphadenopathies
suggestive of pulmonary tuberculosis (Fig. 1a), but tuberculin
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skin test was negative, and Quantiferon-TB Gold was indetermi-
nate, because production of IFN-γ was observed also from cells
not stimulated withMTB-complex-associated antigens (negative
control tube). He did not receive BCG vaccine, and the PPD test
was negative in his parents. This notwithstanding, since clinical
picture and inflammatory markers did not improve, the in vitro
yield of mycobacteria may require weeks, targeted investigations
to exclude immunodeficiencies were in progress, and the pulmo-
nary CT showed a typical picture of TB; 18 days later, a com-
bined therapy for tuberculosis with isoniazid, rifampicin, etham-
butol, and pyrazinamide was started without any result. After
other 20 days, Mycobacterium avium yielded from the initial
gastric lavages. Targeted therapy with ethambutol (20 mg/kg/
day), clarithromycin (15 mg/kg/day), and amikacin (20 mg/kg/
day) was prescribed and continued for 9 months. This led to
disappearance of fever in 5 days, progressive resolution of symp-
toms and signs, and improvement of chest x-rays confirmed by a
CT before stopping therapy. No overt abnormalities were found
in routine hematological and immunological tests: HIV-negative,
total number of T cells and their subpopulations, proliferative
response to mitogens, and IgG levels were all within the normal
ranges. Three months after suspension of therapy, the child de-
veloped a left lateralized seizure with loss of consciousness
followed by winking movements at the left eye and persistent
drowsiness. EEG revealed a post-critical pattern, and the neuro-
logical imaging (CT scan and resonance imaging [MRI]) showed
the presence of multiple encephalic lesions mainly in the right
frontoparietal and occipital lobes with significant perilesional
edema (Fig. 1b). The lumbar puncturewas non-contributorywith
only mild immunoglobulin increase and no identification of in-
fectious agents by cultures, PCRs, or evidence of acid-fast bacilli.
A cerebral biopsy was judged too risky. In the hypothesis of an
encephalic spread of M. avium, combined treatment with
clarithromycin, ethambutol, and amikacin was re-administered
with addition of dexamethasone. After 2 weeks, amikacin was
substituted with levofloxacin (10 mg/kg) and then with rifampi-
cin due to persistent QT prolongation at electrocardiogram
(ECG) after 4 weeks of quinolone treatment. The
antimycobacterial therapy was administered for a total of
13 months without further side effects, leading to resolution of
clinical manifestations, progressive reduction, and then normali-
zation of cerebral lesions at MRI. Analysis of STAT1 phosphor-
ylation in response to IFN-γ, IFN-α, or medium by flow cytom-
etry showed an absence of response to IFN-γ in cells from the
patient as compared with a control subject, while phosphoryla-
tion in response to IFN-α was normal (Fig. 2). Plasma level of
IFN-γwas high (396 pg/ml). Taken together, all data suggested a
genetic defect in IFN-γ receptor subunits. Sanger sequencing of
coding exons of IFNGR1 showed wild-type sequences, while
IFNGR2 genetic testing revealed a homozygous small deletion
in exon 5 (c.663del27, predicted to lead to the in-frame deletion
of residues 222–230 from IFN-γR2 protein), present in hetero-
zygous state in his parents.
Given the poor prognosis of patients with AR complete
IFN-γR deficiency, HSCT was proposed. A 22-year-old male
10 out of 10 HLA-matched unrelated donor was identified
Fig. 1 Chest CT scan of patient with mycobacterial infection and brain
MRI lesions. a Chest CT scan: parenchymal consolidation of left upper
lobe and diffuse lymphadenopathies. b Brain MRI: multiple hypodense
cortical and subcortical lesions in the right frontoparietal and in less extent
in right parietal and occipital lobes with perilesional edema
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(CMVnegative, blood group 0Rh negativewhile patient’s blood
group was BRh positive). Bonemarrowwas chosen as stem cell
source to reduce the risk of graft versus host disease (GvHD).
When, at the age of 4 years and 4 months, the child underwent
HSCT, he was in good health without any symptoms or signs of
infections and normal inflammatory markers from several
months. The myeloablative conditioning included iv busulfan
(total dose 17.6 mg/kg), fludarabine (total dose 160 mg/kg),
and thiotepa (total dose 10 mg/kg). Leviracetam prophylaxis of
seizures was continued. Acyclovir, fluconazole, trimethoprim--
sulfamethoxazole, and intravenous immunoglobulins were given
as standard prophylaxis of infections. Anti-M. avium treatment
that had been suspended for risk of toxicity was re-administered
using rifampicin, ethambutol, clarithromycin, and amikacin.
Given the possible enhancement of the busulfan toxicity, its con-
centration was monitored, but no variation of busulfan dose was
required. Bone marrow infusion contained 9.7 × 108 total nucle-
ated cells/kg and 10.5 × 106 CD34+ cells/kg. GvHD prophylaxis
consisted of anti-thymocyte globulin (ATG, 7.5 mg/kg), short
course of methotrexate (MTX, 10 mg/mq iv on day + 1; 8 mg/
mq iv on days +3, +6 and + 11), and cyclosporine A (CycloA,
3 mg/kg iv starting day − 1 and then adjusted to achieve plasma
concentrations between 100 and 250 ng/mL). The early post-
transplant course was regular with no acute toxicities or severe
infections. Engraftment of platelets and neutrophils were ob-
served on day + 15 and + 18, respectively, and the patient was
discharged from the bone marrow transplantation unit on day +
19. On day + 39, the control of donor-recipient chimerism on
bone marrow nucleated cells showed > 97% donor’s cells. In the
first 100 days after the transplantation, the patient had no signs or
symptoms of GvHD; he only suffered grade 1 renal toxicities
according to Bearman criteria that were treated with oral hydra-
tion and dose modulation of the main nephrotoxic drugs.
Chimerism analyses at + 6 and + 12 months confirmed com-
plete donor’s chimerism on PBMCs. Total T cell and B cell
numbers and IgG levels returned within normal ranges from
+9 months (CD3 + CD4+ 423/uL; CD3 + CD8+ 128/uL;
CD19+ 306/uL; IgG 942 mg/dL without replacement therapy);
at that time, circulating IFN-γ level was within the normal range
(< 50 pg/ml). Cyclosporine tapering was started at + 12 months
with complete stop of immunosuppression 2 months later. The
anti-mycobacterial drugs were progressively discontinued in
parallel with the immune reconstitution, in particular amikacin
was suspended at + 1, rifampicin at + 6, ethambutol at +
12 months, and clarithromycin after suspension of cyclosporine
as well as levetiracetam given the normal EEG and brain MRI.
At the last check, 4 years and 9 months from HSCT, the patient
was in good clinical condition, and he never had signs of HSCT-
related toxicities or of significant infections.
This new patient was affected by an AR complete IFN-γR2
deficiency caused by the homozygous mutation c.663del27 of
exon 5. Notably, the same mutation was found in an Austrian
child of consanguineous parents in whom Vogt et al. [17, 21]
demonstrated that the two in-frame loss-of-function IFN-γR2
alleles encoded misfolded proteins that were abnormally N-
glycosylated with a consequent complete block of the response
Fig. 2 Flow cytometric analysis
of STAT1 phosphorylation after
stimulation of PBMCs with IFN-
γ, IFN-α or medium alone.
STAT1 phosphorylation in
PBMCs from a control subject
(C) or the patient (P) after stimu-
lation with IFN-γ (blue lines, up-
per panels), IFN-α (blue lines,
lower panels), or with medium
alone (green lines). After cell
permeabilization and fixing, cells
were stainedwith anti-pSTAT1 or
control isotype (red lines) and
analyzed by flow cytometry
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to IFN-γ. In our patient, the underlying MSMDwas responsible
for the first disseminated infection withM. avium affecting lung,
lymph nodes, liver, and spleen at 2 years of age. Combined
specific antibiotic therapy for 9 months allowed the control of
the infection to be reached. However, given the severity of the
genetic defect 3 months after its suspension, there was a dramatic
encephalic recrudescence. This suggests that antibiotic treatment
of mycobacterial infections should be continued in these patients
[2, 3]. A recent guideline provides useful recommendations for
treatment of pulmonary disease caused by nontuberculous
mycobacteria in adults [22], but there are no extensive studies
on the prolonged use of some drugs, such as clarithromycin and
quinolones, in pediatric age. To this purpose, it must be noticed
that levofloxacin treatment was stopped due to QT prolongation,
a rare drug-related side effect that can potentially lead to devel-
opment of torsades de pointes, while the other anti-
mycobacterial drugs, even if administered for a total of
36 months, did not elicit any adverse event. A prompt diagnosis
of the immunodeficiency is however needed: in our patient, in
front of the targeted suspect following the isolation ofM. avium
from gastric juice, the diagnosis was made only through in-depth
genetic testing after the presumed mycobacterial infection of the
brain. The child responded again to antibiotic therapy, and a
compatible donor was identified.
HSCT is the only curative therapy for AR complete IFN-γR
deficiency. Twelve cases with IFN-γR1 deficiency who
underwent HSCT have been described: 10 from matched related
donors and 2 frommatched unrelated donors. Highmortality and
high graft rejection rate were noted among this cohort with only
four successful transplantations [9–14]. Main cause of treatment
failure has been ascribed to poor engraftment related to high
IFN-γ serum concentrations typically found in complete
IFN-γR–deficient patients [23]. High level of IFN-γ may cause
cell death by Fas ligand–induced apoptosis and interfere with the
cell cycles of donor HSCs [24, 25]; this negative impact could be
exacerbated if donor alloreactive T cells produce IFN-γ in case
of GvHD. However, at time of HSCT, our patient was in good
health, with no symptoms or signs of infections and normal
inflammatory markers from several months; furthermore, he
did not develop any GvHD. Other five patients with AR
IFN-γR2 deficiencies underwent HSCT. Two siblings received
stem cells frommother and father, respectively. The older brother
after full hematological engraftment developed fulminant
catheter-associated Serratia marcescens septicemia and died,
and the second son was successfully treated with paternal cells
[16]. Another patient after myeloablative conditioning regimen
received an unrelated umbilical cord blood unit 5/6matched [18].
Other two siblings were successfully transplanted with
haplotype-matched bone marrow from the father [20].
Therefore, all the six patients, with AR complete IFN-γR2 defi-
ciencies, despite transitory side effects, showed a hematological
reconstitution and, with the exception of the patient who died of
septicemia, a stable immunological recovery. Since clinical and
biologic characteristics of patients affected by AR complete
IFN-γR1 or IFN-γR2 are comparable, the apparent better re-
sponse in the latter might be accounted for by the small sample
size or by the different therapeutic and prophylactic protocols
rather than by real underlying biologic differences. The EBMT-
ESID initiative collecting HSCT experiences in patients with AR
IFN-yR deficiencies (https://www.ebmt.org/research/studies/
hsct-experience-patients-interferon-gamma-receptor-
deficiencies) may contribute to shed light on this issue and to
optimize preventive and therapeutic protocols. Recently, an anti-
IFN-γmonoclonal antibody (Emapalumab®) has been shown to
reduce the detrimental effects of high levels of IFN-γ in patients
with familial hemophagocytic lymphohistiocytosis [26], suggest-
ing its potential use in the setting of IFN-γR deficiencies too. In
our patient, possible positive aspects of the excellent response
might be (a) his good general conditionwith no overt infection or
abnormal inflammatory markers from several months before
HCST; (b) the choice of a donor with 10 out of 10 HLA-
matched antigens; (c) the bone marrow as stem cell source,
which reduces the risk of GvHD; (d) the vigorous GvHD pro-
phylaxis with ATG, MTX, and CycloA; (e) no sign of GvHD
(and thus no associated production of IFN-γ), (f) the prophylaxis
again viruses, fungi, bacteria, and peumocystosis, (g) the anti-
Mycobacterium avium treatment until the suspension of all im-
munosuppressive drugs, and (h) targeted controls of possible
drug toxicities through a close monitoring of organ functions
and drug concentrations. The absence of any clinical manifesta-
tion at follow-up suggests that the lack of function of IFN-γR2 in
non-hemopoietic tissues does not have a significant clinical im-
pact, although this may be confirmed only by long-term post-
transplant monitoring. In conclusion, this case confirms that at
present, HSCT remains the only curative intervention for the
block of IFN-γR signaling pathway, whereas a future alternative
may be the gene therapy that in mice has been shown to be
effective in restoring IFN-γR function and in protecting from
mycobacterial infections [27].
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